Psilocybin rescues sociability deficits in an animal model of autism
Preprint
Abstract
Autism spectrum disorder (ASD) is characterized by core deficits in social interaction. The classic serotonergic psychedelic psilocybin has been suggested as a therapeutic agent that may ameliorate in the core symptomology of ASD. We found that the acute response to psilocybin was attenuated in the prenatal valproic acid exposure mouse model of ASD, and importantly, psilocybin rescued the social behavioural abnormalities present in these ASD model mice.Keywords
This publication has 28 references indexed in Scilit:
- Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in AutismAutism Research, 2013
- Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood AutismJAMA, 2013
- 5-HT2 Receptor Distribution Shown by [18F] Setoperone PET in High-Functioning Autistic AdultsThe Journal of Neuropsychiatry and Clinical Neurosciences, 2012
- Networking in Autism: Leveraging Genetic, Biomarker and Model System Findings in the Search for New TreatmentsNeuropsychopharmacology, 2011
- Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still countingBrain Research, 2011
- Validating γ Oscillations and Delayed Auditory Responses as Translational Biomarkers of AutismBiological Psychiatry, 2010
- Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behaviorJournal of Neurochemistry, 2010
- Common circuit defect of excitatory-inhibitory balance in mouse models of autismJournal of Neurodevelopmental Disorders, 2009
- Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect BehaviorNeuron, 2007
- Cortical Serotonin 5-HT2A Receptor Binding and Social Communication in Adults With Asperger’s Syndrome: An in Vivo SPECT StudyAmerican Journal of Psychiatry, 2006